Aktis Oncology Starts Second Phase 1b Trial for AKY-2519
Aktis Oncology has initiated the Phase 1b BActinium-2 trial of its drug AKY-2519 for NSCLC and other B7-H3+ tumors. This trial adds to the company's ongoing Phase 1b study in mCRPC, with preliminary data from that study anticipated in 2027.